Topics

Agonistant Antibody Immunotherapy-Mediated Tumor Immunotherapy

Cancer Immunotherapy Tumor Microenvironment Intercellular Communication & Diseases

Agonist antibody-mediated tumor immunotherapy uses antibodies to activate immune-stimulatory receptors rather than block inhibitory checkpoints. The main targets include CD40 on antigen-presenting cells and costimulatory receptors on T and NK cells, including CD137, OX40, GITR, CD27, CD28, and ICOS. This field emerged from the recognition that antitumor immunity requires antigen recognition plus costimulation, and it now aims to convert weak or exhausted immune responses into durable tumor control[1][2][3].

Mechanistically, agonist antibodies ligate costimulatory glycoproteins and deliver activating signals that promote lymphocyte expansion, effector differentiation, survival, cytokine production, and antitumor activity. CD40 agonist antibodies activate antigen-presenting cells, license dendritic cells, promote antitumor T-cell activation, and re-educate macrophages to destroy tumor stroma. OX40 and CD137 agonism supports T-cell survival, proliferation, activation, and tumor-reactive CD8 T-cell expansion. CD27 agonism enhances T-cell proliferation, activation, effector and memory differentiation, and cytotoxic T-cell immunity, especially when paired with T-cell receptor engagement[1][2][4][5].

Disease applications include melanoma, pancreatic cancer, mesothelioma, breast cancer, metastatic solid tumors, recurrent malignant glioma, and combination immunotherapy strategies. CD40 agonist antibodies have shown antitumor activity alone or with chemotherapy, CTLA-4 blockade, PD-1 blockade, or local intratumoral delivery. Intratumoral Fc-engineered CD40 agonism produced tumor reduction, complete responses in melanoma and breast cancer, regression of injected and non-injected lesions, systemic CD8 T-cell activation, and tertiary lymphoid structure formation. Dual OX40/CD137 agonism and OX40 plus 4-1BB agonist combinations are being developed to increase T-cell activation and improve synergy with PD-1/PD-L1 blockade[2][3][6][7].

The main challenge is achieving strong local immune activation without systemic inflammation, cytokine-release toxicity, or autoimmunity. Clinical translation depends on dose, schedule, route of administration, Fcγ receptor engagement, receptor clustering, tumor microenvironment context, and rational combinations. Next-generation designs include Fc-engineered antibodies, FcγR-crosslinking-independent agonists, bispecific agonists, intratumoral delivery, and synthetic costimulation for adoptive cell therapy. Future work should define biomarkers of receptor expression, immune activation, tertiary lymphoid structure formation, and combination sensitivity so agonist antibodies can be deployed as precision immunotherapy rather than broad immune stimulation[1][2][6][7][8].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-13323A CX-5461 dihydrochloride
CX-5461 dihydrochloride is a selective, orally active RNA polymerase I inhibitor. CX-5461 dihydrochloride disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 dihydrochloride upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 dihydrochloride induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 dihydrochloride can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors.
DNA/RNA Synthesis   MDM-2/p53   AMPK   Akt   Autophagy   Apoptosis   Checkpoint Kinase (Chk)  
Musculoskeletal and Skin Disease   Cervical Cancer   Ovarian Cancer   Osteosarcoma  
72
HY-13323 CX-5461
CX-5461 is a selective, orally active RNA polymerase I inhibitor. CX-5461 disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors.
DNA/RNA Synthesis   MDM-2/p53   AMPK   Akt   Autophagy   Apoptosis   Checkpoint Kinase (Chk)  
Musculoskeletal and Skin Disease   Cervical Cancer   Ovarian Cancer   Osteosarcoma  
72
HY-18174 Prexasertib
Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity.
Checkpoint Kinase (Chk)   Apoptosis  
Digestive System Disease   Prostate Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
39
HY-14720 Rabusertib
Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.
Checkpoint Kinase (Chk)   Autophagy  
Pancreatic Cancer   SARS-CoV-2 Infection  
26
HY-10992 AZD-7762
AZD-7762 is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC50 of 5 nM for Chk1.
Checkpoint Kinase (Chk)  
Leukemia/Lymphoma/Myeloma  
26
HY-15532 SCH900776
SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC50 of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively.
Checkpoint Kinase (Chk)  
Cancer   SARS-CoV-2 Infection  
18
HY-10895 SB-334867
SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively. SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
14
HY-106224B Orexin A (human, rat, mouse) acetate
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease  
13
HY-106224 Orexin A (human, rat, mouse)
Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease  
13
HY-109566 Elrelesertib
Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer.
ATM/ATR   Apoptosis   Checkpoint Kinase (Chk)  
Lung Cancer   Breast Cancer   Pancreatic Cancer   Glioma  
13
HY-13946 BML-277
BML-277 is a selective checkpoint kinase 2 (Chk2) inhibitor with an IC50 of 15 nM.
Checkpoint Kinase (Chk)   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation  
10
HY-10805 Almorexant
Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis.
Orexin Receptor (OX Receptor)   Calcium Channel   Caspase   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Hypertension  
9
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-109012 Seltorexant
Seltorexant (JNJ-42847922) is an orally active, high-affinity, and selective orexin-2 receptor (OX2R) antagonist (pKi values of 8.0 and 8.1 for human and rat OX2R). Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
4
HY-N0743 Senkyunolide A
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis.
α-synuclein  
Cancer   Inflammation or Immune System Disease   Depression   Parkinson's Disease  
4
HY-18958 CCT245737
CCT245737 (SRA737) is an orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM.
Checkpoint Kinase (Chk)  
Leukemia/Lymphoma/Myeloma  
4
HY-108829A Abatacept (powder)
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-108829 Abatacept
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Lung Cancer   Melanoma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-P1339A Orexin B, human TFA
Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
2
HY-P99434 Amlitelimab
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis.

Species: Human

Others  
Inflammation or Immune System Disease  
2
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-P99812 Ragifilimab
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
1
HY-P99419 Acasunlimab
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

TNF Receptor  
Cancer  
1
HY-P99014 Cusatuzumab
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML).

Species: Human

Fc Receptor (FcR)   NF-κB  
Inflammation or Immune System Disease   Acute Myeloid Leukemia  
1
HY-P78189 OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi) is a recombinant biotinylated human OX40 (L29-A216) with C-terminal Avi and His tag, which is produced in HEK293.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

1
HY-P991404 AMG-228
AMG-228 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. AMG-228 can be used in advanced solid tumors research.

Species: Human

TNF Receptor  
Cancer  
/
HY-P991556 TQB2916
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research.

Species: Human

TNF Receptor  
Cancer  
/
HY-P992062 Anti-Mouse CD80 Antibody (TKMG48)
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8+ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1.

Species: Mouse

PD-1/PD-L1  
Autoimmune Disease  
/
HY-203876 Sar10
Sar10 (Compound 1) is a component of a bicyclic peptide sequence (βAla-Sar10-A-) for synthesis of multimeric CD137-binding/activating bicyclic peptide ligands.
Drug Intermediate   TNF Receptor  
/
HY-P991465 Anti-CD27 Antibody (M2177)
Anti-CD27 Antibody (M2177) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TNF Receptor  
Cancer  
/
HY-P990241 Anti-Mouse GITR (D265A) Antibody (DTA-1)
Anti-Mouse GITR (D265A) Antibody (DTA-1) is an anti-mouse GITR IgG1 monoclonal antibody. Anti-Mouse GITR (D265A) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (D265A) Antibody (DTA-1) contains the D265A mutation region. Anti-Mouse GITR (D265A) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991510 CDX-1140
CDX-1140 is a fully human IgG monoclonal antibody and CD40 agonist, with a Kd value of 0.01 nM against human targets. The epitope of CDX-1140 locates at CD40 CRD1 and avoids the CD40L binding site. It activates DCs and B cells, drives NF-κB reporter gene activation, exhibits agonist activity independent of FcR cross-linking, and shows a synergistic effect with recombinant CD40L. CDX-1140 does not induce systemic cytokine release, exerts direct and immune-mediated anti-tumor activity in tumor xenografts, and has favorable safety profiles. When used as a local vaccine adjuvant in combination with 6MHP+mBRAF+poly-ICLC, CDX-1140 increases the number of DC-LAMP+ DCs and induces Th1 CD4+ responses in high-risk melanoma. CDX-1140 can be used in studies related to B-cell lymphoma, bladder cancer and high-risk melanoma.

Species: Human

TNF Receptor  
Bladder Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P990280 Anti-Mouse CD27 Antibody (RM27-3E5)
Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor.

Species: Mouse

TNF Receptor   Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P990809 Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3)
Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is an agonistic mouse-derived IgG2a κ antibody, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can stimulate 4-1BB signaling and induce T cell mediated antitumor immunity. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease, such as glioblastoma and retrovirus infection.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P991661 AMG-172 Antibody
AMG-172 Antibody is an anti-CD27L antibody. AMG-172 Antibody can be used for synthesis of ADC AMG-172 (HY-185483).

Species: Human

ADC Antibodies   TNF Receptor   Transmembrane Glycoprotein  
Cancer  
/
HY-P991466 Anti-CD27 Antibody (M2191)
Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TNF Receptor  
Cancer  
/
HY-P11253 DOTA-Bn-CA-170
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
VISTA  
Inflammation or Immune System Disease  
/
HY-P10417B RTDLDSLRTYTL TFA
RTDLDSLRTYTL TFA is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL TFA binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL TFA is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL TFA can be used in the research of cancer immunotherapy and targeted drug development.
Integrin   IFNAR  
Cancer  
/
HY-P992408 MEDI-5083
MEDI-5083 is an Fc fusion protein that targets CD40 and is a CD40 agonist. MEDI-5083 stimulates CD40 signaling via NF-κB activation. MEDI-5083 upregulates MHCII, CD80, and CD86 expression, induces pro-inflammatory cytokine secretion, and enhances IFN-γ secretion by memory CD8+ T cells. MEDI-5083 can be used for the research of melanoma, colon carcinoma, and advanced solid tumors[1][2].

Species: Human

TNF Receptor   NF-κB   MHC   IFNAR  
Colorectal Cancer   Melanoma  
/
HY-P1828 EGFRvIII peptide (PEPvIII)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P10491 MAGE A4 (230-239)
MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies.
Others  
/
HY-P991529 AGEN-2373
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991918 KHK2840
KHK2840 is a potent CD40 agonist with a Kd value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma.

Species: Human

Transmembrane Glycoprotein   Interleukin Related  
Colorectal Cancer   Cancer Immunology   Immunotherapy for Melanoma  
/
HY-P990528 Anti-TNFRSF7/CD27 Antibody
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P991070 ADG-106
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

TNF Receptor  
Triple-Negative Breast Cancer  
/
HY-P10417 RTDLDSLRTYTL
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
Integrin   IFNAR  
Cancer  
/
HY-P991464 IBI37G5
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity.

Species: Human

TNF Receptor  
Cancer  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P990240 Anti-Mouse GITR (LALA-PG) Antibody (DTA-1)
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is an anti-mouse GITR IgG2a monoclonal antibody. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) contains the LALA-PG mutation region. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P99876 Efaprinermin alfa
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein.
Others  
/
HY-P991827 Anti-Mouse CTLA-4 Antibody (UC10-4F10-11)
Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).

Species: Mouse

CTLA-4  
Breast Cancer  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-P11379 ELTLGEFLKL
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of HLA-A*0201. ELTLGEFLKL can be used in the research of tumor immunotherapy.
Survivin   MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P991063 GEN-1053
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992).

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991149 Nesfrotamig
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors.

Species: Human

TNF Receptor  
Breast Cancer   HER2-Positive Gastric Cancer  
/
HY-148775 PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
Biochemical Assay Reagents  
Bacterial Infection   Glioblastoma  
/
HY-P99119A Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3)
Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a mouse-derived IgG2a κ type antibody agonist, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a chimeric antibody of the original LOB12.3 antibody (HY-P990809). Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) contains the LALA-PG mutation region. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease.

Species: Mouse

TNF Receptor  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99057A Varlilumab (anti-CD27)
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P99321 Teneliximab
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991525 2141-V11
2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8+ T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma.

Species: Human

Fc Receptor (FcR)  
Breast Cancer   Bladder Cancer   Melanoma   Glioma  
/
HY-W145481A D-Galacto-D-mannan
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease.
C-type Lectin-like Receptors (CTLRs)   Sirtuin  
Inflammation or Immune System Disease  
/
HY-P991180 TRX-518
TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors[1][2][3].

Species: Human

TNF Receptor  
Cancer  
/
HY-P990018 Boserolimab
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses.

Species: Human

TNF Receptor   NF-κB  
Cancer   Inflammation or Immune System Disease  
/
HY-P99914 Emfizatamab
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.

Species: Human

PD-1/PD-L1   TNF Receptor   CD19   CD3   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-P99572 Tecaginlimab
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P990738 Enristomig
Enristomig (ES-101) is a multispecific antibody. Enristomig is both a PD-L1 antagonist and a conditional agonist of 4-1BB. Enristomig can be used for research on PD-L1 expressing tumors.

Species: Human

TNF Receptor   PD-1/PD-L1  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P990175 Anti-Mouse OX40L/CD134L Antibody (RM134L)
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4+ T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC).

Species: Mouse

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-P991179 MK-4166
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes.

Species: Human

TNF Receptor  
Cancer  
/
HY-P991178 BMS-986156
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies.

Species: Human

TNF Receptor  
Cancer  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-P990017 Englumafusp alfa
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells.

Species: Human

CD19  
Cancer  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P99178 CTX-471
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P10493A NY-ESO-1 (157-165) peptide TFA
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-P990124 Anti-Mouse GITR Antibody (DTA-1)
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

TNF Receptor   NF-κB   Interleukin Related  
Cancer   Inflammation or Immune System Disease  
/
HY-P991636 AK006
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research.

Species: Human

Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-P99836 Cudarolimab
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.

Species: Human

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-P99605 Cinrebafusp alfa
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
EGFR   TNF Receptor  
Cancer  
/
HY-P991336 Ordastobart
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.

Species: Human

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-P990981 Clesitamig
Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC).

Species: Human

CD3  
Cancer   Inflammation or Immune System Disease  
/
HY-P991734 VHB937
VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research.

Species: Human

TREM receptor   Syk   Calcium Channel  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99363 Feladilimab
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P990742 Givastomig
Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma.

Species: Human

TNF Receptor   Claudin  
Cancer   Inflammation or Immune System Disease  
/
HY-P991066 Adimanebart
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992).

Species: Human

nAChR  
Neurological, Eye or Ear Disease  
/
HY-P99057 Varlilumab
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P99249 Vonlerolizumab
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models.

Species: Human

Orexin Receptor (OX Receptor)  
Cancer  
/
HY-P99119 Anti-Mouse 4-1BB/CD137 Antibody (3H3)
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a κ agonistic monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer.

Species: Mouse

TNF Receptor   Bcl-2 Family  
Cancer   Inflammation or Immune System Disease  
/
HY-P990907 Brivekimig
Brivekimig (F-027300252; SAR-442970) is a bispecific nanobody targeting TNF/OX40L. Brivekimig is applicable to research related to hidradenitis suppurativa.

Species: Human

TNF Receptor  
Immunomodulation   Skin Inflammation  
/
HY-P10493 NY-ESO-1 (157-165) peptide
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-159835 Oveporexton
Oveporexton (TAK-861) is an orally active and selective orexin receptor 2 (OX2R) agonist with an EC50 of 2.5 nM. Oveporexton exhibits 3000-fold selectivity for OX2R over OX1R. Oveporexton can be used for the study of hypersomnia disorders including narcolepsy.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease  
/
HY-139559 Vornorexant
Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia research research.
Orexin Receptor (OX Receptor)  
Neurological, Eye or Ear Disease  
/
HY-P99408 Oxelumab
Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P99570 Telazorlimab
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P99159 Ivuxolimab
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc.

Species: Human

Interleukin Related  
Prostate Cancer   Liver Cancer   Melanoma  
/
HY-P990043 Iluzanebart
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP).

Species: Human

Ser/Thr Kinase   TREM receptor  
Inflammation or Immune System Disease  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-P99046 Selicrelumab
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.

Species: Human

TNF Receptor  
Colorectal Cancer   Metastatic Breast Cancer   Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Pancreatic Ductal Adenocarcinoma  
/
HY-133898 Danavorexton
Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms.
Orexin Receptor (OX Receptor)  
/
HY-P99260 Conatumumab
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .

Species: Human

TNF Receptor  
Pancreatic Cancer   Non-Small Cell Lung Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P99056 Utomilumab
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20+ non-Hodgkin lymphomas.

Species: Human

TNF Receptor  
Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-108813 Belatacept
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation. The component ratio of this product is Active ingredient : Excipients = 1:2.4.

Species: Human

Others  
Immunosuppression  
/
HY-P991202 Anti-TSHR Antibody (M22)
Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening.

Species: Human

TSH Receptor   PKA  
Blood or Cardio-cerebrovascular Disease   Graves’ Disease  
/
HY-P99955 Rocatinlimab
Rocatinlimab (AMG 451) (KHK4083) is a fully human immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD).

Species: Human

Orexin Receptor (OX Receptor)  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P9997 Rosnilimab
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-P7113 4-1BBL/TNFSF9 Protein, Human
4-1BBL (4-1BB ligand) is a type II membrane protein of the TNF superfamily, is expressed on antigen-presenting cells. 4-1BB with 4-1BBL can induce T-cell expansion, cytokine induction, differentiation, and upregulation of anti-apoptotic genes as well as protect T cells from activation-induced cell death (AICD). 4-1BBL stimulates T cell proliferation and induces effective anti-tumor immune responses. 4-1BBL is an immunostimulant molecule that interacts with the 4-1BB high-affinity receptor during the antigen presentation, providing costimulatory signals to both CD4+ and CD8+ T cells through the activation of NF-kB, c-Jun, and p38 downstream pathways, triggering pleiotropic effects on the immune system. 4-1BBL/TNFSF9 Protein, Human is a recombinant protein consisting of 184 amino acids (R71-E254) and is produced in E. coli.

Species: Human; Source: E. coli

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules Dendritic Cell CD Proteins Epithelial cell CD Proteins TNF Superfamily Ligands 4-1BBL

/
HY-P70813 OX40/TNFRSF4 Protein, Human (HEK293, Fc)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Human (HEK293, Fc) is a recombinant human OX40 (L29-A216) with C-terminal Fc tag, which is produced in HEK293.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P75427 CD27/TNFRSF7 Protein, Rat (HEK293, Fc)
The CD27/TNFRSF7 protein is predicted to have endopeptidase inhibitor activity, be ethanol responsive, and be membrane localized. Its ortholog of human CD27 has been implicated in lymphoproliferative syndrome 2, emphasizing immune system regulation. CD27/TNFRSF7 Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P78334 OX40/TNFRSF4 Protein, Mouse (HEK293, His-Avi)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Mouse (His-Avi) is a recombinant mouse OX40 (V20-P211) with C-terminal Avi and His tag, which is produced in HEK293.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P78386 4-1BB/TNFRSF9 Protein, Human (HEK293, Fc-Avi)
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human (HEK293, Fc-Avi) is the extracellular part (L24-Q186) of 4-1BB protein, produced by HEK293 cells with C-terminal Avi- and hFc-tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P72884 4-1BB/TNFRSF9 Protein, Mouse (HEK293, His)
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Mouse 4-1BB protein is a surface glycoprotein with a transmembrane domain. 4-1BB/TNFRSF9 Protein, Mouse (HEK293, His) is the extracellular part (V24-L187) of 4-1BB protein, produced by HEK293 cells with C-terminal His-tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P700012AF Animal-Free 4-1BBL/TNFSF9 Protein, Human (His)
4-1BBL/TNFSF9 protein is a cytokine that selectively binds to TNFRSF9 and exerts its effects by inducing the proliferation of activated peripheral blood T cells. As a homotrimer, this ligand demonstrates its potential role in activation-induced cell death (AICD) and may be involved in coordinating homologous interactions between T cells and B cells/macrophages. Animal-Free 4-1BBL/TNFSF9 Protein, Human (His) is the recombinant human-derived animal-Free4-1BBL/TNFSF9 protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

Species: Human; Source: E. coli

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Animal-free Recombinant Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Dendritic Cell CD Proteins Epithelial cell CD Proteins TNF Superfamily Ligands 4-1BBL

/
HY-P75164 GITR Protein, Mouse (HEK293, His)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Mouse (HEK293, His) is a recombinant protein with a C-terminal His label and is produced in HEK293 cells.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P70822 GITR Protein, Human (T45A, HEK293, mFc)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (T45A, HEK293, mFc) is a recombinant protein with a C-terminal Fc label and T at position 45 is mutated to A. It consists of 136 amino acids (Q26-E161) and is produced in HEK293 cells.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P75633 CD27/TNFRSF7 Protein, Human (Biotinylated, sf9, His)
The CD27/TNFRSF7 protein is a receptor for CD70/CD27L and may ensure the survival of activated T cells, suggesting that it plays a crucial role in immune responses. Its association with SIVA1 suggests a regulatory function in the apoptotic pathway. CD27/TNFRSF7 Protein, Human (Biotinylated, sf9, His) is the recombinant human-derived CD27/TNFRSF7 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Human; Source: Sf9 insect cells

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P75634 CD27/TNFRSF7 Protein, Human (HEK293, Fc)
The CD27/TNFRSF7 protein is a receptor for CD70/CD27L and may ensure the survival of activated T cells, suggesting that it plays a crucial role in immune responses. Its association with SIVA1 suggests a regulatory function in the apoptotic pathway. CD27/TNFRSF7 Protein, Human (HEK293, Fc) is the recombinant human-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-rFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P78067 4-1BB/TNFRSF9 Protein, Human (Biotinylated, HEK293, His-Avi)
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human (Biotinylated, HEK293, His-Avi) is the extracellular part (L24-Q186) of 4-1BB protein, produced by HEK293 cells with C-terminal His- and Avi-tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P78068 4-1BB/TNFRSF9 Protein, Human (Biotinylated, HEK293, Fc-Avi)
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the extracellular part (L24-Q186) of 4-1BB protein, produced by HEK293 cells with C-terminal Avi- and hFc-tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P78137 GITR Protein, Human (Biotinylated, HEK293, His-Avi)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (Biotinylated, HEK293, His-Avi) is a biotinylated recombinant protein with a C-terminal Avi label and a C-terminal His label, It consists of 136 amino acids (Q26-E161) and is produced in HEK293 cells.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P78503 OX40/TNFRSF4 Protein, Human (HEK293, His-Avi)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Human (HEK293, His-Avi) is a recombinant human OX40 (L29-A216) with C-terminal Avi and His tag, which is produced in HEK293.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P7125 4-1BB/TNFRSF9 Protein, Human
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human is the extracellular part (E19-S184) of 4-1BB protein, produced by E. coli with tag free.

Species: Human; Source: E. coli

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P75632 CD27/TNFRSF7 Protein, Human (sf9, His)
The CD27/TNFRSF7 protein is a receptor for CD70/CD27L and may ensure the survival of activated T cells, suggesting that it plays a crucial role in immune responses. Its association with SIVA1 suggests a regulatory function in the apoptotic pathway. CD27/TNFRSF7 Protein, Human (sf9, His) is the recombinant human-derived CD27/TNFRSF7 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Human; Source: Sf9 insect cells

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P76216 CD27/TNFRSF7 Protein, Mouse (HEK293, His)
CD27/NFRSF7 Protein acts as a receptor for CD70/CD27L, supporting activated T-cell survival and potentially influencing apoptosis through interactions with SIVA1.It forms homodimers and engages with SIVA1 and TRAF2, indicating diverse roles in cellular processes.CD27/TNFRSF7 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P78594 CD27/TNFRSF7 Protein, Cynomolgus (HEK293, mFc)
CD27/TNFRSF7 Protein lacks conserved residue(s) crucial for feature annotation propagation, suggesting a unique structural characteristic. This peculiarity may influence CD27's functional properties within the TNFR superfamily, emphasizing the need for further investigation to understand its specific roles and regulatory mechanisms in cellular processes. CD27/TNFRSF7 Protein, Cynomolgus (HEK293, mFc) is the recombinant cynomolgus-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of CD27/TNFRSF7 Protein, Cynomolgus (HEK293, mFc) is 172 a.a., with molecular weight of 50-66 kDa.

Species: Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P78599 4-1BB/TNFRSF9 Protein, Rabbit (HEK293, His)
4-1BB/TNFRSF9 Protein lacks conserved residue(s) crucial for feature annotation propagation. 4-1BB/TNFRSF9 Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived 4-1BB/TNFRSF9 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rabbit; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P78794 4-1BB/TNFRSF9 Protein, Mouse (Biotinylated, isoform 2, HEK293, His-Avi)
4-1BB/TNFRSF9 Protein lacks conserved residue(s) crucial for feature annotation propagation. 4-1BB/TNFRSF9 Protein, Mouse (Biotinylated, 188a.a, HEK293, His-Avi) is the recombinant mouse-derived 4-1BB/TNFRSF9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of 4-1BB/TNFRSF9 Protein, Mouse (Biotinylated, 188a.a, HEK293, His-Avi) is 188 a.a., with molecular weight of 30-45 kDa.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P70683 GITR Protein, Human (HEK293, hFc)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (HEK293, hFc) is a recombinant protein with a C-terminal Fc label, It consists of 136 amino acids (Q26-E161) and is produced in HEK293 cells.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P75166 GITR Protein, Human (Biotinylated, HEK293, Fc-Avi)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant protein with a C-terminal Fc label and a C-terminal Avi label, It consists of 161 amino acids (M1-E161) and is produced in HEK293 cells.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P75610 CD137/4-1BB Protein, Canine (HEK293, His)
4-1BB (CD137; TNFRSF9), is a surface glycoprotein, a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. CD137/4-1BB Protein, Canine (HEK293, His) has 185 amino acids (M1-S185), produced by HEK293 cells with C-terminal His-tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P76199 CD137/4-1BB Protein, Rhesus Macaque (HEK293, His)
4-1BB (CD137; TNFRSF9), is a surface glycoprotein, a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. CD137/4-1BB Protein, Rhesus Macaque (HEK293, His) has 186 amino acids (M1-Q186), produced by HEK293 cells with C-terminal His-tag.

Species: Rhesus Macaque; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P78188 OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, Fc)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, Fc) is a biotinylated recombinant human OX40 (L29-A216) with C-terminal hFc tag, which is produced in HEK293.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P78640 GITR Protein, Canine (HEK293, His)
GITR is a type I transmembrane protein. GITR mediates signal transduction through NF-kB and MAPK pathways. Protects T cells from cell death induced by TCR activation. GITR inhibits proliferation and induces apoptosis of Multiple Myeloma (MM) cells in vitro and in vivo. GITR Protein, Canine (HEK293, His) is the recombinant canine-derived GITR protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P70549 OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (187a.a, HEK293, His)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (187a.a, HEK293, His) is a recombinant cynomolgus OX40 (K28-A216) with C-terminal 6*His tag, which is produced in HEK293.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P72631 GITR Protein, Mouse (HEK293, Fc-His)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Mouse (HEK293, Fc-His) is a recombinant protein with a C-terminal Fc label and a C-terminal His label, It consists of 132 amino acids (S22-H153) and is produced in HEK293 cells.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P72743 CD27/TNFRSF7 Protein, Mouse (HEK293, His-Fc)
CD27/NFRSF7 Protein acts as a receptor for CD70/CD27L, supporting activated T-cell survival and potentially influencing apoptosis through interactions with SIVA1.It forms homodimers and engages with SIVA1 and TRAF2, indicating diverse roles in cellular processes.CD27/TNFRSF7 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-hFc, C-6*His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P74335 4-1BB/TNFRSF9 Protein, Mouse (isoform 2, HEK293, Fc)
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Mouse 4-1BB protein is a surface glycoprotein with a transmembrane domain (188-208 a.a.). 4-1BB/TNFRSF9 Protein, Mouse (isoform 2, HEK293, Fc) has 188 amino acids (V24-L211), produced by HEK293 cells with C-terminal rFc-tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P75163 GITR Protein, Rat (HEK293, Fc)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Rat (HEK293, Fc) is a recombinant protein with a C-terminal Fc label, It consists of 121 amino acids (M1-K121) and is produced in HEK293 cells.

Species: Rat; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P75165 GITR Protein, Mouse (HEK293, Fc)
GITR (TNFRSF18) is a member of the TNFR superfamily. GITR promotes T cell activation and proliferation and increases resistance to tumors and viral infections, and exacerbates autoimmune diseases and inflammation processes. GITR Protein, Mouse (HEK293, Fc) is a recombinant protein with a C-terminal Fc label and is produced in HEK293 cells.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P75609 CD137/4-1BB Protein, Canine (HEK293, Fc)
4-1BB is a surface glycoprotein that belongs to the tumor necrosis factor (TNF) receptor superfamily. CD137 promotes apoptosis of endothelial cells (ECs) by inhibiting Nrf2 pathway and up-regulating NF-κB pathway. 4-1BB can be used in anti-tumor research. CD137/4-1BB Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD137/4-1BB protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P75953 OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is a recombinant rhesus macaque OX40 with C-terminal hFc tag, which is produced in HEK293.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P75954 OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (HEK293, His)
OX40 (TNFRSF4), is a receptor for OX40 Ligand. OX40 is preferentially expressed by T cells. OX40 can be activated by OX40 Ligand, thereby functioning as a T cell co-stimulatory molecule. The OX40-OX40 Ligand interaction promotes effector T-cell survival and effectively induces memory T-cell generation, as well as enhances the helper function of Tfh for B cells, and also promotes the differentiation and maturation of DCs. OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is a recombinant rhesus macaque OX40 with C-terminal His tag, which is produced in HEK293.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P76200 CD137/4-1BB Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His)
CD137, also known as 4-1BB, is a protein that exhibits defects in conserved residues required for feature annotation propagation. Specific residues missing in CD137 prevent the propagation of certain functional features associated with this protein. CD137/4-1BB Protein, Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived CD137/4-1BB protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P77574 4-1BB/TNFRSF9 Protein, Mouse (isoform 2, HEK293, His)
4-1BB/TNFRSF9 Protein, crucial with cytokine and protein binding, influences processes like interleukin regulation and cell proliferation.Located externally on the plasma membrane, its expression is notably high in the placenta adult (RPKM 139.4), emphasizing its significance in specific physiological contexts.As the ortholog to human TNFRSF9, it suggests evolutionary conservation of functions across species.4-1BB/TNFRSF9 Protein, Mouse (isoform 2, HEK293, His) is the recombinant mouse-derived 4-1BB/TNFRSF9 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P7810 CD137/4-1BB Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc)
CD137/4-1BB Protein lacks conserved residue(s) crucial for feature annotation propagation. CD137/4-1BB Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is the recombinant cynomolgus-derived CD137/4-1BB protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P7832 CD27/TNFRSF7 Protein, Rhesus macaque (HEK293, His)
CD27/TNFRSF7 Protein lacks conserved residue(s) crucial for feature annotation propagation, suggesting a unique structural characteristic. This peculiarity may influence CD27's functional properties within the TNFR superfamily, emphasizing the need for further investigation to understand its specific roles and regulatory mechanisms in cellular processes. CD27/TNFRSF7 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Rhesus Macaque; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P78614 4-1BB/TNFRSF9 Protein, Rat (HEK293, His)
4-1BB/TNFRSF9 protein is deficient in the conserved residue(s) necessary for propagating feature annotation. 4-1BB/TNFRSF9 Protein, Rat (HEK293, His) is the recombinant rat-derived 4-1BB/TNFRSF9 protein, expressed by HEK293 , with C-His labeled tag. The total length of 4-1BB/TNFRSF9 Protein, Rat (HEK293, His) is 164 a.a., with molecular weight of 28-38 kDa.

Species: Rat; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P78716 GITR Protein, Cynomolgus (HEK293, Fc)
GITR Protein, Cynomolgus (HEK293, Fc) is the recombinant Rhesus Macaque-derived GITR protein, expressed by HEK293, with C-hFc labeled tag.

Species: Rhesus Macaque; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Cytokine Receptors TNF Receptor Superfamily GITR/CD357

/
HY-P704269 CD27/TNFRSF7 Protein, Human (HEK293, mFc)
The CD27/TNFRSF7 protein is a receptor for CD70/CD27L and may ensure the survival of activated T cells, suggesting that it plays a crucial role in immune responses. Its association with SIVA1 suggests a regulatory function in the apoptotic pathway. CD27/TNFRSF7 Protein, Human (HEK293, mFc) is the recombinant human-derived CD27/TNFRSF7 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P704274 CD27/TNFRSF7 Protein, Human (HEK293, His)
The CD27/TNFRSF7 protein is a receptor for CD70/CD27L and may ensure the survival of activated T cells, suggesting that it plays a crucial role in immune responses. Its association with SIVA1 suggests a regulatory function in the apoptotic pathway. CD27/TNFRSF7 Protein, Human (HEK293, His) is the recombinant human-derived CD27/TNFRSF7 protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins B Cell CD Proteins NK Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins TNF Receptor Superfamily CD27

/
HY-P704275 OX40/TNFRSF4 Protein, Human (HEK293, mFc)
OX40/TNFRSF4, a receptor for TNFSF4/OX40L/GP34, crucially acts as a costimulatory molecule in long-term T-cell immunity. Additionally, OX40 functions as a receptor for human herpesvirus 6B/HHV-6B during microbial infections, highlighting its dual role in the adaptive immune response and potential involvement in specific viral interactions. OX40/TNFRSF4 Protein, Human (HEK293, mFc) is the recombinant human-derived OX40/TNFRSF4 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P704970 4-1BB/TNFRSF9 Protein, Human (Biotinylated, 100a.a, HEK293, His-Avi)

Species: Human; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cytokine Receptors TNF Receptor Superfamily 4-1BB

/
HY-P705133 OX40/TNFRSF4 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His-Avi)

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

Cytokines and Growth Factors Immune Checkpoint Proteins CD Antigens Receptor Proteins Biotinylated Proteins TNF Superfamily Stimulatory Immune Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Cytokine Receptors TNF Receptor Superfamily OX40/CD134

/
HY-P81730 OX40L Antibody (YA1475)
OX40L Antibody (YA1475) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to OX40L.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80025 Bad Antibody (YA593)
Bad Antibody (YA593) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bad.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81664 CD70 Antibody (YA1409)
CD70 Antibody (YA1409) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD70.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81761 CD137/4-1BB Antibody (YA1506)
CD137/4-1BB Antibody (YA1506) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD137/4-1BB.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84962 CD137/4-1BB Antibody (YA4654)
CD137/4-1BB Antibody (YA4654) is a non-conjugated antibody, targeting to CD137/4-1BB.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P84330 CD134/OX40L Recepter Antibody (YA4027)
CD134/OX40L Recepter Antibody (YA4027) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84309 4-1BBL Antibody (YA4006)
4-1BBL Antibody (YA4006) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to 4-1BBL.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P810813 OX40L Antibody (YA10056)
OX40L Antibody (YA10056) is a Mouse-derived and non-conjugated IgM Monoclonal antibody, targeting to OX40L.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P810815 RAB5B Antibody (YA10058)
RAB5B Antibody (YA10058) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to RAB5B.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P81509 CD134/OX40L Recepter Antibody (YA1254)
CD134/OX40L Recepter Antibody (YA1254) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81509A CD134/OX40L Recepter Antibody (YA1254)(PBS only)
CD134/OX40L Recepter Antibody (YA1254) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81533 CD27 Antibody (YA1278)
CD27 Antibody (YA1278) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD27.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81533A CD27 Antibody (YA1278)(PBS only)
CD27 Antibody (YA1278) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD27.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81584 4-1BBL Antibody (YA1329)
4-1BBL Antibody (YA1329) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 4-1BBL.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81588 GITR Antibody (YA1333)
GITR Antibody (YA1333) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GITR.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81759 CD134/OX40L Recepter Antibody (YA1504)
CD134/OX40L Recepter Antibody (YA1504) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81770 GITR-L Antibody (YA1515)
GITR-L Antibody (YA1515) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GITR-L.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82571 4-1BBL Antibody (YA2316)
4-1BBL Antibody (YA2316) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 4-1BBL.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82571A 4-1BBL Antibody (YA2316)(PBS only)
4-1BBL Antibody (YA2316) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 4-1BBL.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84309A 4-1BBL Antibody (YA4006)(PBS only)
4-1BBL Antibody (YA4006) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to 4-1BBL.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84330A CD134/OX40L Recepter Antibody (YA4027)(PBS only)
CD134/OX40L Recepter Antibody (YA4027) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84503 CD137/4-1BB Antibody (YA4200)
CD137/4-1BB Antibody (YA4200) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD137/4-1BB.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84503A CD137/4-1BB Antibody (YA4200)(PBS only)
CD137/4-1BB Antibody (YA4200) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD137/4-1BB.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84896 TNFRSF18 Antibody (YA4593)
TNFRSF18 Antibody (YA4593) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TNFRSF18.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84896A TNFRSF18 Antibody (YA4593)(PBS only)
TNFRSF18 Antibody (YA4593) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TNFRSF18.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84953 4-1BBL Antibody (YA7076)
4-1BBL Antibody is a non-conjugated antibody, targeting to 4-1BBL/CD137L.

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P84961 CD134/OX40L Recepter Antibody (YA4653)
CD134/OX40L Recepter Antibody (YA4653) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD134/OX40L Recepter.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84981 CD27 Antibody (YA4673)
CD27 Antibody (YA4673) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD27.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Nanobodies Primary Antibodies

/
HY-P85005 CD70 Antibody (YA4697)
CD70 Antibody (YA4697) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD70.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Nanobodies Primary Antibodies

/
HY-P85054 BID Antibody (YA4746)
BID Antibody (YA4746) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to BID.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P85815 CD27 Antibody (YA5507)
CD27 Antibody (YA5507) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD27.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85859 CD27 Antibody (YA5551)
CD27 Antibody (YA5551) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD27.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P88574 SIVA1 Antibody (YA8258)
SIVA1 Antibody (YA8258) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SIVA1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P88574A SIVA1 Antibody (YA8258)(PBS only)
SIVA1 Antibody (YA8258) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SIVA1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/

Keywords

agonist antibody | tumor immunotherapy | CD40 agonist | OX40 | CD137 | 4-1BB | GITR | CD27 | costimulation | Fc engineering | tertiary lymphoid structure | checkpoint blockade